Article History
Received: 13 April 2017
Accepted: 8 January 2018
First Online: 18 January 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: LJ and PCG have no conflicts of interest to declare. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011–14, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997–99), GlaxoSmithKline (2001–2), Sanofi-Synthelabo (2003) and IMS Health (2013). In 2014–16, TJ was a member of three advisory boards for Boehringer Ingelheim and is holder of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ was a co-signatory of the Nordic Cochrane Centre’s complaint to EMA over maladministration at EMA in relation to the investigation of alleged harms of HPV vaccines and consequent complaints to the European Ombudsman. TJ is also sole author of a complaint to the European Ombudsman over slowness and redactions of clinical study reports of HPV vaccine released by EMA.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.